![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, July 17, 2015 4:46:56 PM
Since there is a significant movement today, I thought I would provide a quick update. As I have said yesterday, this stock is on radar of lots of traders, and therefore, volatility should be expected. TNXP closed very strong today with ‘form 4’ news.
For those, who missed my analysis from yesterday, here is the link:
TNXP TA thoughts 7/16/15
General Updates:
a) The bulls continue to dominate on 30 minutes and hourly chart.
b) This stock likes being in overbought/oversold levels for extended time as we have noted from past. I am not much worried looking at these indicators at this point.
c) Daily chart looks better than yesterday, and with continuation of bulls over next few days, we can expect the trend change indicators to confirm the same. Daily chart has got room to run more.
d) Immediate resistance points would be 8.75-8.85 area followed by 9.32. There are also some hidden resistances in between these price ranges..
e) Following would be a nice support area for this stock – 8.2 – 8.55.
Today, instead of posting daily or hourly chart, I would like to post 5 min chart. TNXP also have history of following steep trend-lines for hours/few days. Last month we saw similar trend-line when it rallied from 7ish to 9ish. History also shows that this pattern is not new for this stock. This trend-line is what I would be focusing on to sell my shares if I want to shorten my position, together with analyzing support/resistance points. Make no mistake here, TNXP is going through chart correction process.
![](http://i.imgur.com/pugxsbC.png?1)
Recent TNXP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:05:23 PM
- Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS) • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024 • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/14/2024 09:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:24:27 PM
- Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/13/2024 09:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/12/2024 09:01:03 PM
- Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/12/2024 01:00:00 PM
- Tonix Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 06/11/2024 09:17:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/11/2024 08:49:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 12:53:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:21:23 PM
- Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split • GlobeNewswire Inc. • 06/06/2024 03:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:05:39 PM
- Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024 • GlobeNewswire Inc. • 06/06/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024 • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:05:27 PM
- Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 12:05:48 PM
- Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024 • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 09:10:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 09:10:36 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM